Nasdaq granted KALA BIO, Inc. continued listing on The Nasdaq Capital Market, requiring a closing bid price of at least $1.00 per share from November 30, 2026 through February 23, 2027. The company had received a bid-price deficiency notice for July 16, 2026 through August 26, 2026.
KALA · KALA BIO, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
KALA BIO, Inc. needs additional time to complete its analysis and disclosure regarding liquidity and capital resources for the quarter ended September 30, 2026, and expects to file no later than the fifth calendar day following the prescribed filing deadline.
KALA BIO will effect a 1-for-30 reverse stock split, reducing outstanding common shares from 19,339,786 to approximately 644,659; split-adjusted Nasdaq trading begins November 16, 2026 under KALA.
KALA BIO, Inc. reported preliminary third-quarter 2026 net loss of approximately $0.8 million, down from $7.6 million, and approximately $7.0 million in cash, cash equivalents and short-term investments with no debt.
KALA BIO, Inc. stockholders approved a reverse stock split at a ratio of not less than 1-for-2 and not greater than 1-for-300. The Board of Directors will determine the timing and publicly announce the selected ratio.
KALA BIO, INC. will hold its 2026 annual meeting on November 3, 2026, seeking stockholder approval for a common-stock reverse split at a ratio of not less than 1-for-2 and not greater than 1-for-300, director elections and other proposals.